Innate Pharma (IPHA) Cash & Equivalents (2017 - 2025)
Innate Pharma's (IPHA) quarterly Cash & Equivalents came in at $32.7 million in Q4 2025, down 53.91% YoY from $71.0 million in Q4 2024, and down 46.21% on a QoQ basis from $60.8 million in Q2 2025.
Innate Pharma (IPHA) Cash & Equivalents (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Cash & Equivalents data on file, last reported at $32.7 million in Q4 2025.
- Quarterly Cash & Equivalents fell 53.91% year-over-year to $32.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $32.7 million (down 53.91% YoY) and the FY2025 annual result came in at $32.7 million, down 53.91% from the prior year.
- Cash & Equivalents retreated to $32.7 million in Q4 2025, from $60.8 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $125.2 million in Q2 2021 to a low of $32.7 million in Q4 2025.
- A 5-year average of $83.3 million and a median of $76.9 million in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2021 — Cash & Equivalents plunged 99.9% — and 2024, when it declined 3.08%.
- Tracing IPHA's Cash & Equivalents over 5 years: stood at $118.7 million in 2021, then dropped by 27.6% to $85.9 million in 2022, then decreased by 11.59% to $76.0 million in 2023, then decreased by 6.6% to $71.0 million in 2024, then plunged by 53.91% to $32.7 million in 2025.
- The last three Cash & Equivalents figures came in at $32.7 million (Q4 2025), $60.8 million (Q2 2025), and $71.0 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | 32.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32.70 Mn |
| Jun 30, 2025 | 60.79 Mn |
| Dec 31, 2024 | 70.95 Mn |
| Jun 30, 2024 | 75.37 Mn |
| Dec 31, 2023 | 75.97 Mn |
| Jun 30, 2023 | 77.76 Mn |
| Dec 31, 2022 | 85.93 Mn |
| Jun 30, 2022 | 109.85 Mn |
| Dec 31, 2021 | 118.69 Mn |
| Jun 30, 2021 | 125.22 Mn |
| Dec 31, 2020 | 163.10 Mn |
| Jun 30, 2020 | 131.54 Bn |
| Dec 31, 2019 | 224.57 Mn |
| Dec 31, 2018 | 173.85 Mn |
| Dec 31, 2017 | 117.00 Mn |